Residual Risk of Trimethylamine‐N‐Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy
Open Access
- 4 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (19) , e027265
Abstract
Background: Trimethylamine N‐oxide (TMAO) contributes to cardiovascular disease through its prothrombotic, proatherothrombotic, and proinflammatory effects. We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual‐antiplatelet therapy and intensive lipid‐lowering therapy and with a low inflammation level (high‐sensitivity C‐reactive protein <2 mg/L on admission). Methods and Results: Patients with ischemic stroke or transient ischemic attack were enrolled from the CNSR‐III (Third China National Stroke Registry) in China. Plasma TMAO and choline concentrations at baseline were measured in 9793 participants using liquid chromatography–mass spectrometry. The primary outcome was a new stroke within 1 year. Multivariable‐adjusted hazard ratios were calculated using Cox regression models to investigate the associations of TMAO and choline with stroke recurrence. Among all patients, elevated TMAO and choline levels were associated with an increased risk of recurrent stroke (adjusted hazard ratios, 1.28 [95% CI, 1.12–1.45]; and 1.50 [95% CI, 1.32–1.71], respectively). Moreover, elevated TMAO and choline levels were associated with an increased risk of recurrent stroke among patients who received dual‐antiplatelet therapy (1.65 [95% CI, 1.28–2.13]; and 1.70 [95% CI, 1.32–2.19], respectively), intensive lipid‐lowering therapy (1.49 [95% CI, 1.15–1.94]; and 1.49 [95% CI, 1.15–1.92], respectively), with high‐sensitivity C‐reactive protein <2 mg/L (1.39 [95% CI, 1.14–1.69]; and 1.88 [95% CI, 1.53–2.30], respectively), and concurrently received dual‐antiplatelet therapy, intensive lipid‐lowering therapy and with high‐sensitivity C‐reactive protein <2 mg/L (3.57 [95% CI, 1.73–7.38]; and 2.19 [95% CI, 1.16–4.16], respectively). Conclusions: TMAO and choline were risk factors for recurrent stroke independent of dual‐antiplatelet therapy, intensive lipid‐lowering therapy at discharge, and low inflammation on admission.Keywords
This publication has 28 references indexed in Scilit:
- Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κBJournal of the American Heart Association, 2016
- Plasma Concentrations of Trimethylamine-N-oxide Are Directly Associated with Dairy Food Consumption and Low-Grade Inflammation in a German Adult PopulationThe Journal of Nutrition, 2016
- Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of AtherosclerosisCell, 2015
- Fish protein increases circulating levels of trimethylamine‐N‐oxide and accelerates aortic lesion formation in apoE null miceMolecular Nutrition & Food Research, 2015
- γ-Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAOCell Metabolism, 2014
- Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular RiskNew England Journal of Medicine, 2013
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Trimethylamine-N-Oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary RegulationCell Metabolism, 2013
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- Flavin-containing monooxygenase 3 and human diseaseExpert Opinion on Drug Metabolism & Toxicology, 2007